Navigation Links
Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies

hout causing any observable toxicity. The studies also showed that different forms of the VTAs could be combined, and that the combination of 2aG4-IL-2 with 2aG4-alpha interferon was significantly more effective in inhibiting tumor growth than either agent alone. In a preclinical model of B-cell lymphoma, tumor growth was inhibited by 85% in the combination-treated group compared with 60% and 65% in animals treated with either 2aG4-IL-2 or 2aG4-alpha interferon, respectively.

"These new data reaffirm the broad potential and versatility of our Vascular Targeting Agent platform for cancer therapy," said Steven W. King, president and CEO of Peregrine. "We have long thought that our anti- phospholipid antibodies would be ideal for the delivery of cytokines for cancer therapy based on their inherent immunostimulatory effects combined with the anti-tumor effects of the cytokines themselves. We are especially pleased with the strong anti-tumor activity observed in a model of B-cell lymphoma, the first non-solid cancer we have successfully addressed using our VTA technology. We are now assessing our options to further develop and commercialize these cytokine fusion proteins for cancer and potentially, viral infections."

The new class of fusion protein agents falls under Peregrine's VTA technology platform for cancer therapy that includes over 200 patents and patent applications covering broad concepts of tumor therapy using agents that target tumor blood vessels. Because interferon is currently part of standard- of-care therapy for virus infections including chronic hepatitis C, Peregrine also intends to assess the utility of the new class as a second-generation treatment for viral infections.

This work was supported by Susan G. Komen for the Cure and a sponsored research agreement with Peregrine Pharmaceuticals Inc.

Number 3539: Inhibition of Tumor Growth by Targeting Cytokines to Phosphatidylserine (PS) on Tumor Vascular Endothelium, Xianming H
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:1/23/2015)... Jan. 23, 2015  MedScope ( www.medscope.org ), the leading ... a 2015 Connected World magazine Connected World ... (mPERS), that can be used anywhere, anytime. The nomination ... In nominating MedScope, Landon Garner , ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
(Date:1/23/2015)... 2015  Pete Rose, baseball,s all-time hits leader, is the new ... Myoflex, Ducere Pharma has announced. "Pete,s a Hall ... have him on board with Myoflex," said Ducere Pharma Chief ... player who is known across all generations. The passion and ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4Pete Rose bets on Myoflex to relieve aches and pains 2
... 6, 2012  PAREXEL International Corporation (NASDAQ: PRXL ... that Ramita Tandon, Global Head, Late Phase Clinical Trials ... Operations at PAREXEL will address innovative approaches to late ... ( SCOPE ), to be held February 7-9, 2012 ...
... New York, February 6, 2012 In the news ... of USD 6.8 billion in 2015, China Osteoporosis Market Will be ... 11:30 GMT, by Transparency Market Research over PR Newswire, we are ... "Market Size of USD 6.8 billion" has been changed to "Market ...
Cached Medicine Technology:PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 2PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 3PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 4CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 2CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 3CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 4
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... of the,nation,s largest providers of emergency department (ED) management ... in Berwyn,Ill., to run its ED starting Jan. 1, ... in 1975 by ED physicians driven to improve the ... CEP America focuses solely on,developing ED solutions for hospitals ...
... ASHP Midyear Clinical,Meeting and Exhibition -- Omnicell, ... provider of,system solutions to acute healthcare facilities, and ... Harvard Medical School located in,the heart ... the,planned installation of Omnicell,s SinglePointe(TM) automated patient-specific,medication management ...
... food costs, many,families are economizing on groceries but one ... about 25 cents per 8-ounce glass, on a gallon ... other beverage option in the,supermarket -- providing key vitamins ... for the entire family. To ensure moms don,t cut ...
... that Dr. Jonathan White will join the Company as head ... 8, 2008. In this role, Dr. White will have ... products to complement Haemonetics, blood management solutions portfolio. , ... CEO, said, "As the global leader in blood management solutions ...
... Maine, Dec. 8 IDEXX Laboratories, Inc. (Nasdaq: ... E. Brown, PhD as Corporate Vice President, Instrument Research ... Brown will oversee instrument development, manufacturing, and the worldwide ... "Bill,s extensive R&D and manufacturing management experience is distinctively ...
... Inc. (Nasdaq: HGSI ) today announced that it will sponsor ... 3 trial of Albuferon(R) (albinterferon alfa-2b) in chronic hepatitis C. , ... , The conference call will be hosted by ... 8:15 am Eastern Time. , , Investors ...
Cached Medicine News:Health News:CEP America Partners With MacNeal Hospital to Provide Emergency Department Management, Staffing 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 3Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 3Health News:Dr. Jonathan White Joins Haemonetics as Head of Research and Development 2Health News:IDEXX Laboratories Names William Brown Corporate Vice President 2Health News:Human Genome Sciences to Sponsor Conference Call 2
The Adjustable Large Fixator is a one-piece fixator with a radiolucent body. It has a multifunctional design pivoting pin clamp for use in ankle or tibial plateau fractures....
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
... the Pennig Minifixator, combines the advantage of secure ... tissue dissection is not necessary, since in general, ... fixation in the hand has required bridging of ... (Asche and Burny) because of the design of ...
... The two principal goals of the DJD® II ... the elbow and to protect the articular surfaces ... allowed by a hinge which is designed to ... integrated distraction mechanism prevents the articular surfaces from ...
Medicine Products: